A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

Phase 2

Completed

• Conditions: Medulloblastoma
• Interventions: Drug: LDE225; Drug: TMZ

• Registration Number: NCT01708174
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.

Detailed Description

This study was a single-arm study of the efficacy and safety of oral sonidegib in patients with Hh-pathway activated relapsed medulloblastoma. It was initially designed as a randomized, controlled, open-label phase III study of adults and children with Hh-pathway activated MB whose disease had failed standard of care therapy, including radiation therapy (RT). The original study consisted of a randomized controlled part and a non-randomized uncontrolled part. Approximately 69 patients were to be randomized in a 2:1 ratio to receive sonidegib oral suspension or the active control, temozolomide (TMZ) capsules. Randomization was to be stratified according to age, \<18 years versus ≥ 18 years. Approximately 40 patients were to receive sonidegib in the non-randomized uncontrolled part of the study. Following the enrollment of 11 patients, the study was amended to become a phase II single-arm study with only sonidegib, and the target enrollment was changed to 20 patients. Prior to the study amendment, TMZ participants whose disease progressed while on TMZ were permitted to crossover to sonidegib. After the amendment, participants receiving TMZ were crossed over to sonidegib.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2012-10-11
• Study First Submitted QC: 2012-10-15
• Study First Posted: 2012-10-16
• Study Start: 2013-05-06
• Primary Completion: 2016-10-05
• Study Completion: 2016-10-05
• Results First Submitted: 2017-03-31
• Results First Submitted QC: 2017-05-16
• Results First Posted: 2017-06-14
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-07
• Last Update Posted: 2017-08-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Patients with histologically confirmed diagnosis of MB, who have experienced relapse or progression after standard-of-care therapy including radiotherapy. Patients currently receiving steroids must have been on a stable (or decreasing) dose for at least 5 days before initiating study therapy.

• Only patients with a test result, using the 5-gene Hh signature assay, indicating Hhpathway activated MB are eligible for this study. All available tumor material obtained at any time during the course of the patient's disease should be submitted for these analyses

• At least one measurable lesion defined as lesion(s) that can be accurately measured in at least two dimensions and is ≥ 10 mm in each dimension by Gadolinium (Gd)-MRI, irrespective of slice thickness/reconstruction interval, for CNS lesions and CT or MRI (with or without contrast) for non-CNS lesions. All patients with CNS lesions must have a brain MRI with and without gadolinium and a spine MRI with gadolinium within 2 weeks prior to first dose of study treatment.

• Performance Status corresponding to ECOG score of 0, 1, or 2:

  1. Karnofsky performance status score ≥ 50 for patients >16 years of age
  2. Lansky performance status score ≥ 50 for patients ≤ 16 years of age

• Adequate bone marrow function as defined as:

  1. Peripheral absolute neutrophil count (ANC) ≥ 1.5 x 109/L
  2. Platelet count ≥ 80 x 109/L
  3. Hemoglobin (Hgb) ≥ 9 g/dL

• Serum CK ≤1.5 ULN

Read More

Exclusion Criteria

• Prior treatment with a Smoothened inhibitor Systemic anticancer treatment within 2 weeks before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and monoclonal antibodies).
• Focal radiation therapy within 4 weeks before first dose of study treatment, or full spinal radiotherapy within 3 months before first dose of study treatment.
• Patients who have neuromuscular disorders that are associated with elevated CK (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
• Patients receiving treatment with medications that are known to be strong inhibitors or inducers of CYP3A4/5 or are metabolized by CYP2B6 and CYP2C9, that have narrow therapeutic indices that cannot be discontinued at least 2 weeks before first dose of study treatment and for the duration of the study
• Patients receiving unstable or increasing doses of corticosteroids. If patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms, dose must have been stabilized (or decreasing) for at least 5 days before first dose of study treatment.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Sonidegib (LDE225)	LDE225	600 mg orally for adults and 500 mg/m2 orally for children
Temozolamide (TMZ)	TMZ	150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016	from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016	ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). Assessments after crossover were not included for TMZ participants.

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS) According to IRC From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016	from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016	PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). TMZ participants without event prior to crossover were censored.
PFS According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016	from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016	PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause. PFS was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma.
Percentage of Participants With ORR According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016	from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016	ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR). ORR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. Assessments after crossover were not included for TMZ patients.
Duration of Response (DoR) According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016	from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016	DoR was defined as the time from the first documented onset of confirmed PR or CR to the date of PD/relapse or death due to medulloblastoma. DoR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. TMZ participants without an event prior to crossover were censored.
Overall Survival (OS) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016	from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016	OS was defined as the time from date of randomization to date of death due to any cause. All deaths are considered, including deaths occurred after crossover for TMZ participants.
Pharmacokinetics (PK): Summary of Plasma Trough Concentrations for Sonidegib (LDE225)	Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 and 53	Blood samples were collected for assessment. The children's group was analyzed up until week 25 only.

Trial Locations

Locations (9)

Children's Hospital of Pittsburgh Dept of Oncology; 🇺🇸 Pittsburgh, Pennsylvania, United States

Dana Farber Cancer Institute SC-7; 🇺🇸 Boston, Massachusetts, United States

Novartis Investigative Site; 🇬🇧 Leeds, United Kingdom

Cincinnati Children's Hospital Medical Center Division of Hema/Onco.; 🇺🇸 Cincinnati, Ohio, United States

Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Dept Onc; 🇺🇸 Baltimore, Maryland, United States

Columbia University Medical Center- New York Presbyterian Dept of Oncology; 🇺🇸 New York, New York, United States

Ann & Robert H. Lurie Children Dept of Oncology; 🇺🇸 Chicago, Illinois, United States

University of Texas/MD Anderson Cancer Center SC-3; 🇺🇸 Houston, Texas, United States

Seattle Cancer Care Alliance Dept Oncology; 🇺🇸 Seattle, Washington, United States